Tucatinib and T-DM1 for HER2-positive brain-metastasis tumors
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This Phase 2 study tests tucatinib plus T-DM1 (ado-trastuzumab emtansine) in people with HER2-positive metastatic solid tumors that have spread to the brain. It aims to shrink brain and body tumors and help control cancer that is progressing in the brain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cancer that is HER2-positive (based on approved lab tests on tumor tissue).
- Your brain MRI shows brain metastases that do not need urgent local treatment right away.
- You have measurable tumor outside the brain or at least evaluable disease.
- You can be any age 18 or older, and you can do your usual daily activities (ECOG 0–2).
- Your blood counts, liver, and kidney tests meet required safety limits from recent labs.
- Your heart pumping function is strong enough (left ejection fraction/ LVEF at least 50%).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted drug (Enhertu) with precise radiation (SRS) for people whose HER2-positive breast cancer has spread to the brain. It aims to see if this combo is safe and effective for treating brain metastases.
This Phase 2 trial studies tucatinib combined with oral etoposide and trastuzumab in people with metastatic HER2-positive breast cancer, aiming to slow cancer growth. You may be eligible if you previously had progression on a similar HER2-targeted treatment or cannot take capecitabine for medical reasons.
This trial tests whether adding neratinib to T-DXd (trastuzumab deruxtecan) works better than T-DXd alone for women with HER2-positive breast cancer that has spread to the brain. It is for those who have not had these specific drugs before.
This trial tests a drug called T-DXd in people with advanced non-squamous lung cancer that has a specific HER2 gene change (mutation) and has spread to the brain but isn't causing symptoms. The goal is to see if the drug can shrink tumors and help control the cancer.
This Phase 2 trial tests a combination of tucatinib and capecitabine (taken by mouth) plus trastuzumab delivered into the spinal fluid, to treat breast cancer that has spread to the leptomeninges (lining around the brain/spinal cord). It may help reduce cancer activity in the spinal fluid and improve symptoms.
This trial tests how well an imaging test can predict the effectiveness of the drug T-DXd in people with HER2-positive breast cancer that has spread to the brain. It aims to see if a special scan can help guide treatment.
Hear when a new Metastatic Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.